On the stock market since 2022, it operates in the world of health and science. It has 13 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 40% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 59% a year on average.
Sales run at $2.7M a year. A small number, but proof the product has real buyers.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
A loss of $7.6M against $2.7M in annual sales.
The stock sits at $0.96. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.7 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, LUCY sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: LUCY is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.